{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:27:21Z","timestamp":1720744041728},"reference-count":9,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,11]]},"DOI":"10.7759\/cureus.64331","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:45:48Z","timestamp":1720709148000},"source":"Crossref","is-referenced-by-count":0,"title":["Rituximab-Associated Liver Toxicity Without Known Viral Reactivation"],"prefix":"10.7759","author":[{"given":"Taha","family":"Huda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fawaz","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hariharasudan","family":"Mani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shereen M","family":"Gheith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitri","family":"Skandan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Rituximab. (2018). Accessed. May 7, 2024: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548249\/."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5505\/tjh.2012.98853","article-title":"Rituximab-related reversible hepatocellular damage","volume":"29","author":"Toprak SK","year":"2012","unstructured":"Toprak SK, Karaku\u015f S. Rituximab-related reversible hepatocellular damage. Turk J Haematol. 2012, 29:422-4. 10.5505\/tjh.2012.98853","journal-title":"Turk J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2010.0806","article-title":"A case of rituximab-induced hepatitis","volume":"25","author":"Del Prete CJ","year":"2010","unstructured":"Del Prete CJ, Cohen NS. A case of rituximab-induced hepatitis. Cancer Biother Radiopharm. 2010, 25:747-8. 10.1089\/cbr.2010.0806","journal-title":"Cancer Biother Radiopharm"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201310001-01215","article-title":"Acute hepatocellular damage secondary to rituximab-induced hepatitis","volume":"108","author":"Upadhyay H","year":"2013","unstructured":"Upadhyay H, Sherani K, Vakil A, Cervellione K, Patel A. Acute hepatocellular damage secondary to rituximab-induced hepatitis. Am J Gastroenterol. 2013, 108:S356-7.","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2020-0009","article-title":"Rituximab-induced autoimmune hepatitis: a case study and literature review","volume":"3","author":"Galiatsatos P","year":"2020","unstructured":"Galiatsatos P, Assouline S, Gologan A, Hilzenrat N. Rituximab-induced autoimmune hepatitis: a case study and literature review. Can Liver J. 2020, 3:381-6. 10.3138\/canlivj-2020-0009","journal-title":"Can Liver J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.25259\/JSSTD_9_2019","article-title":"Rituximab induced transaminitis in pemphigus foliaceus","volume":"1","author":"Joy N","year":"2019","unstructured":"Joy N, Sobhanakumari K, Celine MI, Mathew R, Athira S. Rituximab induced transaminitis in pemphigus foliaceus. J Skin Sex Transm Dis. 2019, 1:45-7. 10.25259\/JSSTD_9_2019","journal-title":"J Skin Sex Transm Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20413","article-title":"Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia","volume":"80","author":"Qazilbash MH","year":"2005","unstructured":"Qazilbash MH, Qu Z, Hosing C, Couriel D, Donato M, Giralt S, Champlin R. Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia. Am J Hematol. 2005, 80:43-5. 10.1002\/ajh.20413","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001836","article-title":"RECAM: A new and improved, computerized causality assessment tool for DILI diagnosis","volume":"117","author":"Hayashi PH","year":"2022","unstructured":"Hayashi PH, Lucena MI, Fontana RJ. RECAM: A new and improved, computerized causality assessment tool for DILI diagnosis. Am J Gastroenterol. 2022, 117:1387-9. 10.14309\/ajg.0000000000001836","journal-title":"Am J Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078856","article-title":"Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments","volume":"8","author":"Latus J","year":"2013","unstructured":"Latus J, Klein R, Koetter I, et al.. Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. PLoS One. 2013, 8:e78856. 10.1371\/journal.pone.0078856","journal-title":"PLoS One"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/255447-rituximab-associated-liver-toxicity-without-known-viral-reactivation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T14:45:53Z","timestamp":1720709153000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/255447-rituximab-associated-liver-toxicity-without-known-viral-reactivation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":9,"URL":"https:\/\/doi.org\/10.7759\/cureus.64331","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}